Novartis to Join Glaxo & Sanofi in Clinical Trial Data Transparency Effort

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn


Novartis AG (NYSE:NVS) announced in a press release Wednesday that it will be joining rival pharmaceutical companies such as GlaxoSmithKline Plc (NYSE:GSK) in a clinical trial data transparency effort. Novartis will now allow researchers to request access to patient level data on newly approved innovative medicines in the U.S. and European Union via an internet portal known as Idea Point, which is also used by competitors Glaxo and Sanofi SA (NYSE:SNY).

The company also said it is “committed to enhancing Clinical Study Report summaries for all new pivotal studies to include easy to understand consumer language and additional interpretation of the data” by the end of 2014.

“Novartis has taken action to extend our leadership regarding clinical data transparency and access to data by researchers. This is designed to further advance science and innovation which can benefit patients,” stated Tim Wright, Novartis’ Global Head of Development. “We also believe that patient rights and privacy remains paramount, and recognize that such data should not be released without the express consent of the patient,” a press release stated Wednesday.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business